会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Hydrazide-containing CFTR inhibitor compounds and uses thereof
    • 含酰肼的CFTR抑制剂化合物及其用途
    • US20050239740A1
    • 2005-10-27
    • US11093749
    • 2005-03-29
    • Alan VerkmanNitin SonawaneChatchai Muanprasat
    • Alan VerkmanNitin SonawaneChatchai Muanprasat
    • A61K31/165A61K31/195A61K31/47A61K31/7012
    • A61K31/165A01K67/027A01K2227/105A01K2267/0306A61K31/195A61K31/47A61K31/7012C07D215/38Y02A50/471
    • The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.
    • 本发明提供用于抑制囊性纤维化跨膜传导调节蛋白(CFTR)的组合物,药物制剂和方法,其可用于研究和治疗CFTR介导的疾病和病症。 本发明的组合物和药物制剂可以包含一种或多种含酰肼的化合物,并且还可以包含一种或多种药学上可接受的载体,赋形剂和/或佐剂。 在某些实施方案中,本发明的方法包括给予患有CFTR介导的疾病或病症的患者,有效量的含酰肼的化合物。 在其它实施方案中,本发明提供了抑制CFTR的方法,其包括使受试者中的细胞与有效量的含酰肼化合物接触。 此外,本发明的特征在于CFTR介导的疾病的非人动物模型,其通过以足以抑制CFTR的量向非人动物施用含酰肼的化合物来产生该模型。